New Migraine Abortive Telcagepant Performs Well In Trials
Last year, we looked at Phase II clinical trials of MK-0974, an investigational oral calcitonin gene-related pepitide (CGRP) receptor antagonist, a new type of Migraine abortive. That medication has now been named telcagepant, and is showing great promise as a new Migraine abortive. When I spoke with lead researcher, Dr. Tony Ho, last year, he commented "MK-0974 has a novel new mechanism for relief. Nearly 70% get pain relief at two hours. The results are excellent for sustained relief at 24 hours. The adverse even rate is similar to placebo."
In the latest Phase III study, telcagepant proved safe and effective in treating Migraines and caused fewer side effects than Zomig...
Continue reading New Migraine Abortive Telcagepant Performs Well In Trials.